Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2024. The Group reported revenue growth of 10% (10% in constant currency) to $1.569 billion (compared to $1.427 billion in H1 2023). We have made excellent progress in the first […]
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced that it has recently signed an exclusive licencing agreement with AFT Pharmaceuticals (AFT) for the registration and commercialization of Combogesic® IV, an intravenous, opioid-free pain relief medicine for the short term symptomatic treatment of acute pain in adults and the reduction of fever, in Saudi Arabia, […]
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Chief Executive Officer of Hikma, said: “The good momentum during the first half has continued, enabling us to upgrade full year guidance in two of our three businesses. Our Branded business is performing […]
London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. Under the terms of the agreement, Hikma has an exclusive license to commercialise Oregovomab in 18 Middle East and North Africa […]
Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, report its interim results for the six months ended 30 June 2023. During the first half of 2023, core group revenue grew 18% to $1.427 billion (compared to H1 2022: $1.213 billion), driven by a strong performance in all three businesses. Core […]
